Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI)

CUSIP: 48576U106

Q4 2021 13F Holders as of 31 Dec 2021

Holder snapshot 7 signals
Share change
-565,704
Put/Call ratio
342%
SEC-reported price per share
$6.43
Number of holders
138
Value change
-$3,383,122
Number of buys
73
Open additional details 1 more signal available
Number of sells
62
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
22,658,403

Security key

48576U106

Report period

Q4 2021

Institutions

138

Top holders

10

Ownership snapshot

Top reported holders of KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
BlackRock Finance, Inc.
Disclosed value leader
BlackRock Finance, Inc.
Comparable rows
0/15
Latest evidence
30 Sep 2021
13F Highest disclosed value: $51,160,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

BlackRock Finance, Inc. has the largest disclosed position value at $51.16M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BlackRock Finance, Inc.'s linked filing trail.
Disclosed position value Top 5
BlackRock Finance, Inc. $51.16M
STATE STREET CORP $46.68M
Palo Alto Investors LP $31.33M
VANGUARD GROUP INC $21.2M
Rubric Capital Management LP $19.65M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$51,160,000
8,790,318 shares
— 30 Sep 2021
STATE STREET CORP
13F
Company
13F
—
denominator unverified
$46,676,000
8,019,999 shares
— 30 Sep 2021
Palo Alto Investors LP
13F
Company
13F
—
denominator unverified
$31,329,000
5,383,052 shares
— 30 Sep 2021
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$21,201,000
3,642,699 shares
— 30 Sep 2021
Rubric Capital Management LP
13F
Company
13F
—
denominator unverified
$19,647,000
3,375,758 shares
— 30 Sep 2021
Delphi Management Partners VIII, L.L.C.
13F
Company
13F
—
denominator unverified
$13,170,000
2,263,006 shares
— 30 Sep 2021
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2021

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
138
Shares
54,170,305
Rows available
138
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2021 vs Q1 2026 Across Filers

Q1 2026 holders
1
Q4 2021 holders
138
Holder diff
137
Investor Q1 2026 Shares Q4 2021 Shares Share Diff Share Chg % Q1 2026 value Q4 2021 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .